Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

Carlos García-Echeverría

doi:10.1016/j.bmcl.2010.05.099

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4308-12. doi: 10.1016/j.bmcl.2010.05.099. Epub 2010 Jun 1.

Author

Carlos García-Echeverría¹

Affiliation

¹ Oncology Drug Discovery, Sanofi-Aventis, Vitry-sur-Seine, France. Carlos.Garcia-Echeverria@sanofi-aventis.com

PMID: 20561789
DOI: 10.1016/j.bmcl.2010.05.099

Abstract

Over the past few years a number of components of the PI3K/mTOR pathway have been the subject of intense drug discovery activities both in pharmaceutical companies and in academia. This review article summarizes progress made in the identification and development of allosteric and ATP-competitive kinase inhibitors of mTOR and their potential therapeutic use in oncology.

Publication types

Review

MeSH terms

Adenosine Triphosphate / metabolism
Allosteric Regulation
Antineoplastic Agents / chemistry*
Antineoplastic Agents / therapeutic use
Humans
Neoplasms / drug therapy*
Phosphatidylinositol 3-Kinase / metabolism
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors / chemistry*
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / chemistry
Pyrimidines / therapeutic use
Signal Transduction
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism

Substances

Antineoplastic Agents
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors
Pyrimidines
Adenosine Triphosphate
Phosphatidylinositol 3-Kinase
TOR Serine-Threonine Kinases